Licensing deals

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.

Gabrielle Masson Sep 25, 2025 7:00am

Biopharma biobucks decline, while upfront deal payments rise

Sep 24, 2025 11:30am

Cyclerion emerges from latest pivot as neuro biotech

Sep 24, 2025 4:15am

Angelini signs $550M-plus neuro pact with South Korean biotech

Sep 22, 2025 1:47pm

MRI image of a brain next to a model of DNA

VectorY pens $1.2B pact to use Shape's brain-penetrating capsid

Sep 18, 2025 9:25am

Stethoscope and red heart with pink background

US VC launches another biotech with China-licensed asset

Sep 17, 2025 10:30am